Key points Investigational therapies aim to inhibit the specific immunologic mechanisms behind plaque psoriasis without widely affecting the normal immune system. Pathways targeted by investigational therapies include Janus kinase, tumor necrosis factor-α, interleukin-17, and interleukin-23. Phase II and phase III…
Key points Combination therapies of biologics and systemic agents for psoriasis treatment can potentially enhance efficacy of treatment, increase onset of remission, and decrease side effects by allowing for dose reductions. Potential therapeutic combinations examined include methotrexate paired with biologics;…
Key points Ustekinumab is a human immunoglobulin G κ monoclonal antibody that binds to the p40 protein subunit shared by interleukin-12 (IL-12) and IL-23 cytokines. Ustekinumab is safe and efficacious for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis.…